Guidance on Perindopril Erbumine

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Perindopril Erbumine

Form/Route: Tablet /Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 8 mg
   Subjects: Normal healthy males and females, general population
   Additional Comments: Female subjects enrolled in the BE studies should not be pregnant, and if applicable, should practice abstention or contraception during the study.

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 8 mg
   Subjects: Normal healthy males and females, general population
   Additional comments: Please see comments above.

Analytes to measure (in appropriate biological fluid): Perindopril and the active metabolite, perindoprilat in plasma.

Bioequivalence based on (90% CI): Perindopril.
Please submit the metabolite data as supportive evidence of comparable therapeutic outcome. For the metabolite, the following data should be submitted: individual and mean concentrations, individual and mean pharmacokinetic parameters, and geometric means and ratios of means for AUC and Cmax.

Waiver request of in-vivo testing: 2 mg and 4 mg based on (i) acceptable bioequivalence studies on the 8 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times:
Please note that a Dissolution Methods Database is available to the public at the OGD website at [http://www.fda.gov/cder/ogd/index.htm](http://www.fda.gov/cder/ogd/index.htm). Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Finalized May 2008